What should I know about blood clot risk during Multiple Myeloma treatment

Blood Clot Risk in Multiple Myeloma Treatment

Blood clots are a real concern during multiple myeloma treatment, and it's important you understand this risk so you can work with your care team to prevent them. Let me explain what you need to know.

Why Blood Clots Happen During Myeloma Treatment

According to the NCCN Guidelines for Multiple Myeloma, blood clot risk is highest in the first 6 months after diagnosis. This happens because:

• Certain myeloma medications increase clotting risk, particularly immunomodulators (drugs like lenalidomide and thalidomide)
• High-dose corticosteroids (dexamethasone) used in treatment can increase clotting
• The cancer itself affects your blood's ability to clot normally
• Your reduced mobility during treatment can slow blood flow

How Doctors Assess Your Personal Risk

Your care team won't give everyone the same blood clot prevention—they'll assess YOUR specific risk using scoring systems. According to NCCN Guidelines, doctors consider factors like:

• Your age (older patients have higher risk)
• Whether you've had blood clots before
• Your kidney function
• Other medical conditions you have
• Which specific medications you're taking
• Your activity level

Blood Clot Prevention Options

If your doctor determines you need blood clot prevention, NCCN Guidelines recommend several options:

For lower-risk patients:

• Aspirin (81-325 mg daily)

For higher-risk patients, doctors may choose:

• Low-molecular-weight heparin (LMWH) like enoxaparin
• Direct oral anticoagulants: rivaroxaban or apixaban
• Fondaparinux
• Warfarin (with INR monitoring)

Important note: The NCCN Guidelines point out that myeloma patients were underrepresented in some major clinical trials for these medications, so your doctor's experience with myeloma specifically matters.

Duration of Prevention

According to NCCN Guidelines:

• If you're on active myeloma therapy: Blood clot prevention continues indefinitely while you're being treated
• If you've completed treatment: Prevention typically continues for 3-6 months, though longer periods may be considered based on your individual situation

What You Should Do

Questions to ask your oncology team:

1. "Based on my specific situation, what's my blood clot risk level?" (This helps you understand why they're recommending—or not recommending—prevention)

2. "Which blood clot prevention medication do you recommend for me, and why?" (Different medications have different pros and cons for different people)

3. "How long will I need to take blood clot prevention?" (This helps you plan ahead)

4. "What symptoms should I watch for that might indicate a blood clot?" (Common warning signs include leg swelling, chest pain, shortness of breath, or leg pain)

5. "Are there any interactions between my blood clot prevention medication and my myeloma treatments?" (Important for safety)

6. "If I develop a blood clot while on prevention medication, what happens to my myeloma treatment?" (According to NCCN Guidelines, if you develop a clot while on immunomodulator therapy, you'll typically continue full-dose anticoagulation as long as you're on that myeloma therapy)

Key Takeaway

Blood clot prevention during myeloma treatment is personalized—not everyone needs it, and the type of prevention varies. Your care team will balance the benefit of preventing clots against the bleeding risks of anticoagulation medications. This is an important conversation to have early in your treatment, and it's worth revisiting if your treatment plan changes.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.